- Home
- SLXN vs LRHC Comparison
SLXN vs LRHC Comparison
Compare SLXN & LRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- LRHC
- Stock Information
- Founded
- SLXN 2008
- LRHC 2004
- Country
- SLXN Israel
- LRHC United States
- Employees
- SLXN N/A
- LRHC N/A
- Industry
- SLXN
- LRHC
- Sector
- SLXN
- LRHC
- Exchange
- SLXN NYSE
- LRHC Nasdaq
- Market Cap
- SLXN 6.9M
- LRHC 6.7M
- IPO Year
- SLXN N/A
- LRHC 2023
- Fundamental
- Price
- SLXN $0.93
- LRHC $0.15
- Analyst Decision
- SLXN Strong Buy
- LRHC
- Analyst Count
- SLXN 1
- LRHC 0
- Target Price
- SLXN $5.00
- LRHC N/A
- AVG Volume (30 Days)
- SLXN 3.6M
- LRHC 20.7M
- Earning Date
- SLXN 05-21-2025
- LRHC 04-15-2025
- Dividend Yield
- SLXN N/A
- LRHC N/A
- EPS Growth
- SLXN N/A
- LRHC N/A
- EPS
- SLXN N/A
- LRHC N/A
- Revenue
- SLXN N/A
- LRHC $69,448,786.00
- Revenue This Year
- SLXN N/A
- LRHC N/A
- Revenue Next Year
- SLXN N/A
- LRHC N/A
- P/E Ratio
- SLXN N/A
- LRHC N/A
- Revenue Growth
- SLXN N/A
- LRHC 118.67
- 52 Week Low
- SLXN $0.21
- LRHC $0.09
- 52 Week High
- SLXN $13.56
- LRHC $3.36
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- LRHC 42.41
- Support Level
- SLXN N/A
- LRHC $0.09
- Resistance Level
- SLXN N/A
- LRHC $0.19
- Average True Range (ATR)
- SLXN 0.00
- LRHC 0.03
- MACD
- SLXN 0.00
- LRHC -0.00
- Stochastic Oscillator
- SLXN 0.00
- LRHC 45.45
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has five reportable segments namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management and Real Estate Brokerage Services (Commercial). It derives maximum revenue from Real Estate Brokerage Services (Residential) segment.